FDA 483 - JIANGSU GRAND XIANLE PHARMACEUTICAL CO., LTD
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of JIANGSU GRAND XIANLE PHARMACEUTICAL CO., LTD identified a significant deficiency related to the lack of adequate stability data for a critical intermediate material. The firm failed to provide sufficient data to support the retest date, with initial stability studies failing specifications and subsequent studies being unrepresentative or conducted prior to analytical method validation. This indicates a serious lapse in quality control and data integrity practices.
- Product Type
- Drugs
ID · e7168545-50e8-44c8-9eee-805b89843059